Key result
Combined immunosuppressive therapy successfully treated a case of giant cell myocarditis that presented as rapidly progressive heart failure following COVID-19.
Why the study?
Does combined immunosuppressive therapy improve outcomes in a patient with giant cell myocarditis following COVID-19?
Does combined immunosuppressive therapy improve outcomes in a patient with giant cell myocarditis following COVID-19?
Combined immunosuppressive therapy can successfully treat giant cell myocarditis following COVID-19.
Hypothesis-generating for combined immunosuppression in post-COVID giant cell myocarditis; prospective trials needed before practice change.
In this case report, we present a 46-year-old lady who has developed a rapidly progressive heart failure after an episode of COVID-19. The pathologic examination of her endomyocardial biopsy specimens was compatible with GCM and she was successfully treated with a combined immunosuppressive therapy regimen.
No takes yet. Share an insight, caveat, or question.
Amiri et al. (2021) studied this question. Combined immunosuppressive therapy successfully treated a case of giant cell myocarditis that presented as rapidly progressive heart failure following COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: